 |
|
Research identifies first method for testing, assessing drug treatments for Chagas' disease
April 21, 2008Athens, Ga. - Chagas' disease is a tropical parasitic sickness that currently affects more than 16 million people, with a staggering 100 million at risk, largely in the tropical areas of South and Central America. And yet the main drug used to treat the disease is highly toxic and causes serious side effects.
Now, new research just published by scientists at the University of Georgia has identified for the first time a sensitive method for testing and assessing the efficacy of treatments for Chagas' disease. The study could lead to new treatments for long-term sufferers of a disease that can be fatal.
"It is the first time we've been able to identify a set of measurements to determine whether or not a drug for Chagas actually works," said Rick Tarleton, distinguished research professor of cellular biology and a faculty member at UGA's Center for Tropical and Emerging Global Diseases.
The research was published today in the online edition of the journal Nature Medicine. Co-authors, also from the University of Georgia, are postdoctoral associate Juan Bustamante and master's degree student Lisa Bixby.
The research presents the first and only evidence that the current drug therapies for Chagas' disease can actually completely cure the infection. Still, current treatments have potentially severe side effects and are thought to be effective in less than 50 percent of those treated. More important, the model the team developed can be used for the development of better drugs against Trypanosoma cruzi, the parasite that causes the disease.
"We also found that the immunological markers of cure in this system, which we developed in mice, provide a means to monitor drug treatment efficacy in humans, something that has been the biggest impediment to developing new drugs," said Tarleton.
There's a fourth finding more important to the big picture of immunology, however. This study shows that chronic infections do not by default exhaust the immune system.
"Current dogma on chronic infections is that constant stimulation of the immune system eventually wears it out, which is one of the problems in treating such disorders as HIV/AIDS," said Tarleton. "This study shows that one can have an infection for more than a year, but, when cured, the immune system develops a stable, protective memory."
This idea of "memory" is at the heart of the study, and it involves T-cells, specifically one kind called cytotoxic or "killer" T-cells, which are blood-borne white blood cells that destroy T. cruzi-infected cells in the case of Chagas' disease and virally infected and tumor cells in other cases. Tarleton and his colleagues documented the development of stable killer T-cell "memory" following drug-induced cure of a chronic infection. In other words, when the body is cleared of parasites, the killer T-cells, which may have been "exhausted" by battling the persistent infection, bounce back and recall how to do their job.
The implications of the study could be considerable, Tarleton said. The T. cruzi parasite is passed to humans from the bite of blood-sucking assassin bugs, which go by many names, including "kissing bugs." The infection can also be acquired through contaminated blood transfusions and by eating food contaminated with parasites.
In its first stages, the disease often causes no more than a local swelling at the point of the bite. This acute phase often passes, but the malady, if untreated, can then enter a chronic phase that can last for decades and cause heart disease and intestinal disorders. In many cases, Chagas', named for the Brazilian scientist who first described it nearly a century ago, is fatal.
While several hundred thousand people in the United States may have the disease, these are largely immigrants from Latin American countries. The disease, however, is a major public health issue in all of South America and kills as many as 50,000 people each year, according to some estimates, making it the most significant parasitic disease of the Americas, Tarleton said.
University of Georgia
The research was published today in the online edition of the journal Nature Medicine. Co-authors, also from the University of Georgia, are postdoctoral associate Juan Bustamante and master's degree student Lisa Bixby.
The research presents the first and only evidence that the current drug therapies for Chagas' disease can actually completely cure the infection. Still, current treatments have potentially severe side effects and are thought to be effective in less than 50 percent of those treated. More important, the model the team developed can be used for the development of better drugs against Trypanosoma cruzi, the parasite that causes the disease.
"We also found that the immunological markers of cure in this system, which we developed in mice, provide a means to monitor drug treatment efficacy in humans, something that has been the biggest impediment to developing new drugs," said Tarleton.
There's a fourth finding more important to the big picture of immunology, however. This study shows that chronic infections do not by default exhaust the immune system.
"Current dogma on chronic infections is that constant stimulation of the immune system eventually wears it out, which is one of the problems in treating such disorders as HIV/AIDS," said Tarleton. "This study shows that one can have an infection for more than a year, but, when cured, the immune system develops a stable, protective memory."
This idea of "memory" is at the heart of the study, and it involves T-cells, specifically one kind called cytotoxic or "killer" T-cells, which are blood-borne white blood cells that destroy T. cruzi-infected cells in the case of Chagas' disease and virally infected and tumor cells in other cases. Tarleton and his colleagues documented the development of stable killer T-cell "memory" following drug-induced cure of a chronic infection. In other words, when the body is cleared of parasites, the killer T-cells, which may have been "exhausted" by battling the persistent infection, bounce back and recall how to do their job.
The implications of the study could be considerable, Tarleton said. The T. cruzi parasite is passed to humans from the bite of blood-sucking assassin bugs, which go by many names, including "kissing bugs." The infection can also be acquired through contaminated blood transfusions and by eating food contaminated with parasites.
In its first stages, the disease often causes no more than a local swelling at the point of the bite. This acute phase often passes, but the malady, if untreated, can then enter a chronic phase that can last for decades and cause heart disease and intestinal disorders. In many cases, Chagas', named for the Brazilian scientist who first described it nearly a century ago, is fatal.
While several hundred thousand people in the United States may have the disease, these are largely immigrants from Latin American countries. The disease, however, is a major public health issue in all of South America and kills as many as 50,000 people each year, according to some estimates, making it the most significant parasitic disease of the Americas, Tarleton said.
University of Georgia
Chagas Current Events and Chagas News RSSUCSF marks a milestone with 500th transplant in heart and lung program
UCSF marked a milestone this week with the 500th procedure in its Thoracic Transplant Program, which specializes in transplantation of the heart and lung.
Survival rates exceed national averages for UCSF heart, liver and lung transplant programs
One-year survival rates for patients receiving heart, liver and lung transplants at UCSF Medical Center exceed national averages at statistically significant levels, according to new data compiled by the Scientific Registry of Transplant Recipients (SRTR).
New screening strategy for detection of chagas disease in children
A new targeted screening strategy could make the diagnosis and treatment of Chagas disease more feasible in low-resource settings, concludes a new study, publishing on December 26, 2007, in the open-access journal PLoS Neglected Tropical Diseases.
New drug combination shows promise for African sleeping sickness
A small clinical trial in Uganda, conducted within a long-established Médecins Sans Frontières (MSF) treatment program for African sleeping sickness, has found that a new combination treatment using the drugs nifurtimox and eflornithine holds promise and deserves further evaluation.
Study finds multiple neglected tropical diseases effectively treated with drugs
The neglected tropical diseases are a group of 13 infectious diseases, including elephantiasis, hookworm, African sleeping sickness and trachoma, which affect more than 1 billion people worldwide, most of whom live in extreme poverty.
Data on Life Expectancy Show Many Countries Clustered in High Mortality Traps
Growing recognition of the importance of health as a contributing factor to economic development and societal change has prompted the Proceedings of the National Academy of Sciences (PNAS) to add a new subsection in Sustainable Health to its existing section on Sustainable Development.
Leeches ferry infection among newts
Parasite-carrying bloodsucking leeches may be delivering a one-two punch to newts, according to biologists, who say the discovery may provide clues to disease outbreaks in amphibians.
Bioprospecting not biopiracy
By training professionals in high-biodiversity regions to advance the drug discovery process in-country, a novel program drives drug discovery costs down as it promotes tropical biodiversity conservation.
A case of mistaken molecular identity
Researchers in Argentina have determined that night blindness is a new clinical symptom of Chagas disease.
Parasite genome sequences offer hope for new drugs and vaccines, Science studies say
Scientists have sequenced and compared the genomes of three of the parasites responsible for sleeping sickness, Chagas disease and leishmaniasis, three devastating diseases of the developing world.
More Chagas Current Events and Chagas News Articles
 | Chaga by Ian McDonald |
| Chagas' Disease Vectors, Vol 3: Biochemical Aspects & Control by Rodolfo R. Brenner | |
| Curare and Curare-like Agents in Honour of Professor C. Chagas. by A.V.S. (ed) De Reuck | |
| Chagas disease after organ transplantation--Los Angeles, California, 2006.: An article from: Morbidity and Mortality Weekly Report by L. Mascola, B. Kubak, Radhakrishna S., T. Mone, R. Hunter, D.A. Leiby, M. Kuehnert, A. Moore, F. Steurer, G. Lawrence, H. Kun This digital document is an article from Morbidity and Mortality Weekly Report, published by Thomson Gale on July 28, 2006. The length of the article is 1075 words. The page length shown above is based on a typical 300-word page. The article is delivered in HTML format and is available in your Amazon.com Digital Locker immediately after purchase. You can view it with any web browser.Citation... | |
 | 21st Century Complete Medical Guide to Chagas Disease, Trypanosomiasis, Authoritative Government Documents, Clinical References, and Practical Information for Patients and Physicians (CD-ROM) by PM Medical Health News This up-to-date electronic book on CD-ROM provides the best collection available anywhere of official Federal government information and documents on the subject of Chagas Disease. This CD-ROM uses next-generation search technology that allows complete indexing and makes all files on the disc fully searchable. For patients, practical information is provided in clearly written patient education... |
| Chaga 1ST Edition by William Lipkind | |
| Trypanosomiasis and leishmaniasis with special reference to Chagas' disease (Ciba Foundation symposium) | |
| Trypanosomiasis and Leishmaniasis with Special Reference to Chagas' Disease (Ciba Foundn. Symposium S) | |
| Chagas' Disease and the Nervous System (Scientific Publication) | |
| Kazimir Malevich, 1878-1935: Tekeningen uit de collectie van de Khardzhiev-Chaga Kunststichting (SMA cahiers) |
| © 2008 BrightSurf.com |